|
|
|
|
Vol. 11, Issue 4, 1241-1255, April 2000
Department of Biochemistry, Emory University School of Medicine, Atlanta, Georgia 30322-3050
Submitted October 29, 1999; Revised January 21, 2000; Accepted January 28, 2000| |
ABSTRACT |
|---|
|
|
|---|
A family of three structurally related proteins were cloned
from human cDNA libraries by their ability to interact preferentially with the activated form of human ADP-ribosylation factor 3 (ARF3) in
two-hybrid assays. The specific and GTP-dependent binding was later
confirmed through direct protein binding of recombinant proteins. The
three proteins share large (
300 residues) domains at their N termini
that are 60-70% identical to each other and a shorter (73 residues)
domain at their C termini with 70% homology to the C-terminal
"ear" domain of
-adaptin. Although GGA1 is found predominantly
as a soluble protein by cell fractionation, all three proteins were
found to localize to the trans-Golgi network (TGN) by
indirect immunofluorescence. The binding of GGAs to TGN was sensitive
to brefeldin A, consistent with this being an ARF-dependent event.
Thus, these proteins have been named Golgi-localizing,
-adaptin ear
homology domain, ARF-binding proteins, or GGAs. The finding that
overexpression of GGAs was sufficient to alter the distribution of
markers of the TGN (TGN38 and mannose 6-phosphate receptors) led us to
propose that GGAs are effectors for ARFs that function in the
regulation of membrane traffic through the TGN.
| |
INTRODUCTION |
|---|
|
|
|---|
ADP-ribosylation factors (ARFs) are 21-kDa GTP-binding proteins
that constitute a subfamily of the Ras superfamily (Donaldson and
Klausner, 1994
; for reviews, see Boman and Kahn, 1995
; Moss and
Vaughan, 1998
). Results from several laboratories have pointed to a
central role for ARFs in regulating some aspect of membrane traffic,
particularly to and from the Golgi, and more recently from the
trans-Golgi network (TGN) (Stamnes and Rothman, 1993
; Traub
et al., 1993
; Ooi et al., 1998
; Hirst et
al., 1999
). ARFs were originally found to localize to the Golgi
(Stearns et al., 1990b
). Assays of endoplasmic reticulum
(ER)-Golgi (Balch et al., 1992
), intra-Golgi (Taylor
et al., 1992
), endosome fusion (Lenhard et al.,
1992
), and nuclear vesicle fusion (Boman et al., 1992
) were
used to define a role for ARF in each assay, and presumably in those
transport processes. However, in several of these cases, ARF was found
not to be required for the transport/fusion activity but only for
inhibition of the assay by the nonhydrolyzable GTP analogue GTP
S
(Gant and Wilson, 1997
; Happe and Weidman, 1998
). Thus, an obligate
role for ARF in any of these steps is uncertain. However, a model that
has emerged is that ARFs recruit multimeric coat complexes to the sites
of vesicle buds and play a regulatory role in vesicle formation.
Six currently defined coat protein complexes are thought to be
recruited to membranes by ARF or an ARF family member. Two of these
coat complexes are heptameric (COP-I and COP-II) and four are tetramers
(adaptin complexes AP-1, AP-2, AP-3, and AP-4). COP-I-coated vesicles
function in the transport of vesicles between the Golgi and the
intermediate compartment (Cosson et al., 1996
; Gaynor and
Emr, 1997
). COP-II, whose recruitment to membranes involves activation
of the ARF homologue SAR1, mediates export from the ER (Barlowe
et al., 1994
). The four adaptin complexes share structural
relatedness between homologous subunits and are recruited to membranes
in concert with ARFs. AP-1 is found associated with sites of protein
export from the TGN and on TGN-derived vesicles (Stamnes and Rothman,
1993
; Traub et al., 1993
; Hirst and Robinson, 1998
). AP-2
associates with plasma membranes in an ARF-sensitive manner (West
et al., 1997
) and is found on endosomes derived from the
plasma membrane. AP-3 (Dell'Angelica et al., 1997
; Simpson et al., 1997
; Ooi et al., 1998
) and AP-4
(Dell'Angelica et al., 1999
; Hirst et al., 1999
)
are involved in transport within the endosomal-lysosomal system and in
the transport of non-clathrin-coated vesicles from the TGN, respectively.
Much of the early work on the role of ARF in coat protein recruitment
was fueled by results with the macrolide antibiotic brefeldin A (BFA)
because of its remarkable ability in live cells to cause protein coats
(e.g., COP-I [Donaldson et al., 1990
] and AP-1 [Traub
et al., 1993
]) on the Golgi to rapidly fall off and the
uncoated Golgi membranes to fuse with the ER (Lippincott-Schwartz et al., 1989
). BFA was shown to inhibit an ARF-specific
guanine nucleotide exchange factor in crude membrane fractions (Helms and Rothman, 1992
; Randazzo et al., 1993
) and later
directly on purified ARF guanine nucleotide exchange factors (Peyroche
et al., 1996
, 1999
; Mansour et al., 1999
; Togawa
et al., 1999
). Thus, until another site of BFA action is
defined, it is reasonable to conclude that a protein whose localization
is rapidly (within seconds to a few minutes) and dramatically altered
by BFA addition to live cells lies downstream of an ARF-dependent step.
It is evident from both genetic and biochemical studies in yeast and
mammalian cells that, in addition to their effects on membrane traffic,
ARFs regulate other cellular processes and must do so through regulated
interactions with a variety of effectors, distinct from those involved
in membrane traffic. In addition, it is not clear if the effects of ARF
on vesicular traffic are direct or only mediated by interactions
with coat proteins. To identify novel effectors for activated ARFs, we
initiated a two-hybrid screen of human cDNA libraries with the use of a
dominant activated mutant of ARF3 ([Q71L]ARF3) as bait. Among the
effectors identified were a group of three proteins, termed GGA1, GGA2,
and GGA3 (for Golgi-localizing,
-adaptin ear homology domain,
ARF-binding proteins), that share extensive sequence identity and that
include a region at the C terminus with marked homology to an adaptin
subunit. We describe the direct and GTP-dependent binding of ARF3 to
GGA1 and provide data from in vivo studies of cells overexpressing GGA
proteins that support a model in which GGAs act as ARF-sensitive components in protein transport from the TGN.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Materials
Unless specified otherwise, chemicals and reagents were purchased from Sigma Chemical (St. Louis, MO). Radiolabeled nucleotides were purchased from Amersham (Arlington Heights, IL). Yeast and bacterial media reagents were purchased from Difco (Detroit, MI).
Yeast Two-Hybrid Assay Components
Yeast strains Y190 (MATa gal4 gal80 his3 trp1-901 ade2-101
ura3-52 leu2-3,-112 +URA3::GAL
lacZ,
LYS2::GAL(UAS)
HIS3 cyhr) and Y187
(MAT
gal4 gal80 his3 trp1-901 ade2-101 ura3-52 leu2-3,-112 met
URA3::GAL
lacZ),
plasmids pAS2 and pACT2, and a B-cell library in pACT were the generous
gift of Steve Elledge (Baylor University, Houston, TX). The
yeast strains are constructed with two readouts for an interaction of
histidine auxotrophy and
-galactosidase expression with the use of
the Gal4 binding domain (BD) and activation domain system (Durfee
et al., 1993
). Plasmid pBG4D was obtained from Dr. Rob
Brazas (University of California, San Francisco) to make C-terminal
constructs of ARF with the BD. The ORF of human ARF3 was cloned into
pAS2 with the use of NdeI and BamHI sites and
into pBG4D at the BamHI site. In addition to wild-type ARF3, we also subcloned two mutant alleles of ARF, [Q71L]ARF3, a dominant activating mutant, and [N126I]ARF3, a dominant negative mutant. Any
DNA amplified by PCR was sequenced to confirm that no errors were
introduced by the polymerase.
The expression of each ARF-BD fusion protein was confirmed by
immunoblotting. Proteins in yeast lysates were resolved
by electrophoresis on SDS-PAGE gels, transferred to nitrocellulose, and
probed with either mAb 12CA5 against the hemagglutinin (HA) epitope
incorporated at the C terminus of the BD or ARF3-specific polyclonal
antibody R-1023 (Cavenagh et al., 1996
).
Two-Hybrid Screen
Transformation of Y190 with a plasmid encoding the activated ARF
mutant construct [Q71L]ARF3-BD yielded strain YAB324. This strain was
transformed with each of two human cDNA libraries, a B-cell library in
pACT (8 × 105 transformants) and a kidney
library in pGAD10 (9 × 105 transformants;
Stratagene, La Jolla, CA), and transformants were selected for
histidine auxotrophy on minimal medium lacking histidine and containing
25 mM 3-aminotriazole. After reselection on 3-aminotriazole, colonies
were assayed for
-galactosidase activity, as described previously
(Breeden and Nasmyth, 1985
). Filters were incubated at 30°C for 30 min to 3 h, with color scoring at regular intervals. Obvious blue
color development within 3 h was considered positive. The
[Q71L]ARF3-BD plasmid, carrying a gene conferring sensitivity to
cycloheximide, was next lost by growth of potential positive strains on
plates containing cycloheximide. Only those strains that tested
negative in the
-galactosidase assay after losing the ARF plasmid
were investigated further. These were then tested in two-hybrid assays
in Y190 strains carrying either lamin or cdk2 as partners to confirm
the specificity of the interaction with [Q71L]ARF3. As a final
selection and to enrich for potential ARF effectors or
GTPase-activating proteins (GAPs), each library plasmid was also
transformed into Y190 carrying either the wild-type ARF3-BD construct,
pAB155, or the negative dominant mutant [N126I]ARF3 construct,
pABH3-3. Only those library inserts encoding proteins that interacted
preferentially with the activated mutant of ARF3 were pursued.
Library plasmids were rescued from each positive strain and confirmed
to be of library origin by restriction digestion analysis. Each library
plasmid was then transformed into Y190 or YAB324 cells to test for
two-hybrid activity alone or to confirm the positive reactivity with
[Q71L]ARF3-BD, respectively. Library inserts in those plasmids
encoding proteins that interacted less well with ARF3 than with the
activated mutant were then sequenced in both directions by automated
DNA sequencing. Initial sequence analyses were performed with the use
of BLAST (Altschul et al., 1990
) and FASTA (Pearson and
Lipman, 1988
) against the GenBank and dbEST databases. Alignments of
complete sequences were obtained with the use of Multalign (Corpet,
1988
).
Yeast Methods
All yeast transformations were performed with the use of the
LiOAc method of Ito et al. (1983)
with denatured herring
sperm DNA as a carrier (Schiestl and Gietz, 1989
). Plasmids were
rescued from the yeast as described by Hoffman and Winston (1987)
,
followed by plasmid purification on a Qiagen (Chatsworth, CA) miniprep column.
Northern Blotting
Northern blotting was performed with the use of the Multiple
Human Tissue I blot (Clontech, Palo Alto, CA), as described in the
manufacturer's protocol. Each probe was ~500 base pairs (bp) in
length and was labeled by incorporating
[
-32P]dCTP by random priming with the use of
the kit from Life Technologies (Grand Island, NY). Blots were exposed
to Kodak (Rochester, NY) XAR-5 film for 5-46 h. The same filter was
reprobed and used to develop Northern blots for each of the GGAs.
Complete stripping was confirmed by exposure to film before reprobing
and by the differences in message size, without residual bands
appearing. An actin probe was used as a control for RNA loading after
all GGA probes were completed.
5' Rapid Amplification of cDNA Ends
The 5' end of the GGA1 cDNA was amplified by PCR from a human brain Marathon cDNA library (Clontech) with the use of two gene-specific primers and adaptor primer AP1. The PCR product was subcloned into pCR2.1 by TA cloning (Invitrogen, Carlsbad, CA). Colonies were selected by colony hybridization with a third gene-specific primer, confirmed by restriction digestion, and sequenced by automated sequencing. No identical sequences were found in either GenBank or dbEST.
Antibody Production
Antibodies to GGA1 were raised in two rabbits by HTI Bioproducts (Ramona, CA) with the use of GST-GGA1(145-639) as the antigen. Subcutaneous injections in complete Freund's adjuvant were followed by three boosts in incomplete Freund's adjuvant. All data shown were obtained with the use of serum from rabbit R-79709.
Immunoblotting
Immunoblotting was performed as described
previously (Cavenagh et al., 1996
; Boman et al.,
1999
). Antibodies to GGA1 (R-79709) or ARF3 (R-1023) were used at a
1:2000 dilution. Bound antibodies were detected with HRP-linked
secondary antibodies (Amersham) and ECL detection reagents (Amersham).
Recombinant Proteins
ARF proteins were expressed in bacteria and purified as
described previously (Randazzo et al., 1995
). The cDNA
encoding GGA1(145-639) was subcloned into pGEX5X-2 (Pharmacia,
Piscataway, NJ) after PCR amplification to add appropriate restriction
sites. This construct directs the expression of the N-terminal fusion
protein GST-GGA1(145-639). Expression of the fusion protein was
induced with isopropylthio-
-galactoside in BL21 cells and detected
on Coomassie brilliant blue-stained SDS-PAGE gels or by
immunoblotting with an anti-GST antibody (Stratagene). Fusion proteins were purified by lysing the bacteria with a French press and removing insoluble material by centrifugation at 100,000 × g (35,000 rpm, Ti45 rotor, 30 min, 4°C).
Glutathione-agarose beads were added to the supernatant (S100) and
incubated for 1 h at 4°C with constant mixing; then they were
washed three times with 10 volumes of TND (50 mM Tris, pH 8.0, 100 mM
NaCl, 1 mM DTT). GST-GGA1 was eluted from the beads with the use of TNG
(50 mM Tris, pH 8.0, 100 mM NaCl, 10 mM reduced glutathione) in three batches of 2 volumes each at room temperature. Proteins were
concentrated as needed with a Microcon 10 ultrafiltration unit
(Amicon, Beverly, MA). All protein concentrations were determined by
the amido black method (Schaffner and Weissmann, 1973
).
Glutathione-Agarose Affinity Chromatography
The S100 from bacterial lysates containing GST alone or GST-GGA1
was incubated with glutathione-agarose beads for 30 min at 4°C. The
beads were washed twice with TND and once with binding buffer (25 mM
HEPES, pH 7.0, 2 mM EDTA, 1 mM MgCl2, 100 mM
NaCl, 1 mM DTT, 100 µg/ml BSA, 0.1% Triton X-100) and then incubated with ARF3 or [Q71L]ARF3 (10 µM) that had been preincubated with either GTP
S or GDP (100 µM) for 20 min at room temperature. The beads were then washed three times with binding buffer containing 10 µM nucleotide. Bound proteins were eluted from the beads with an
equal volume of 2× Laemmli's sample buffer and run on a 12% SDS-PAGE
gel. Duplicate gels were either stained with Coomassie brilliant blue
or developed by immunoblotting with the use of a
polyclonal rabbit antiserum (R-1023; Cavenagh et al., 1996
) to detect human ARF3.
Nucleotide-binding Assays
Quantitative nucleotide-binding assays were performed by filter
trapping as described (Kahn and Gilman, 1986
; Randazzo et al., 1995
) with the use of [35S]GTP
S as ligand.
Microinjection, Transfections, and Immunofluorescence
Normal rat kidney (NRK) fibroblasts were grown in RPMI medium with L-glutamine (Life Technologies) plus 10% FBS at 37°C and 5% CO2. Purified GST-GGA1(145-639) was exchanged into 100 mM KPO4, pH 7.4, and concentrated to 4 mg/ml. Protein was mixed with 0.6 mg/ml lysine-fixable FITC-dextran (Molecular Probes, Eugene, OR) to allow detection of injected cells and injected into the cytosol of NRK cells with an Eppendorf Scientific (Westbury, NY) micromanipulator and transjector.
GGA1, GGA1(145-639), GGA2, and GGA3 were subcloned into pcDNA3.1 (Invitrogen) containing an HA epitope tag at the N terminus (a gift from Drs. Lixin Zhang and Haian Fu, Emory University). Transient transfections of NRK cells with the pcDNA3-derived plasmids were performed with the use of the FuGene6 transfection reagent (Boehringer Mannheim, Indianapolis, IN) in the presence of serum. Control transfections contained pcDNA3 with no insert. Cells were fixed 18-24 h after transfection.
Cells were fixed with 2% formaldehyde in PBS for 10 min at room
temperature, followed by permeabilization with 0.2% saponin. Cells
were stained for indirect immunofluorescence with antibodies to GGA1
(rabbit polyclonal R-79709), ARF (mouse monoclonal 1D9; Cavenagh
et al., 1996
), mannosidase II (a gift from K. Moremen [University of Georgia, Athens, GA] and M. Farquhar [University of
California, San Diego, CA]; Moremen et al., 1991
),
-COP
(EAGE peptide rabbit polyclonal; Pepperkok et al., 1993
),
mannose 6-phosphate receptor (M6PR; a gift from K. von Figura,
Georg-August Universität, Göttingen, Germany), TGN38
(kindly provided by G. Banting, University of Bristol, Bristol, United
Kingdom), AP-1 (A36120, mouse monoclonal to
-adaptin; Transduction
Laboratories, Lexington, KY), or AP.6 (raised against the
-subunit
of AP-2; a gift from Dr. Linton Traub, Washington University, St.
Louis, MO). Secondary antibodies against mouse or rabbit immunoglobulin
G were labeled with Texas Red or FITC, respectively (Cappel
Laboratories, Durham, NC). Cells were observed and photographed with
the use of a Zeiss (Thornwood, NY) Axiophot or Olympus (Tokyo, Japan)
BX-60 microscope equipped with a 100× objective. Controls were
performed to ensure against bleed through between different filters
when double staining was performed.
During the characterization of the GGA1 antiserum, it was noted that when cells were permeabilized with 0.1% Triton X-100, we observed mitochondrial staining, as determined by colocalization with Mitotracker (Molecular Probes, Eugene, OR). This is likely the result of cross-reactivity with a 72-kDa band seen on immunoblots, because it was shown to localize to mitochondria by cell fractionation (see RESULTS) and the mitochondrial staining pattern was not affected by overexpression of GGA1. In addition, no evidence of a mitochondrial distribution was detected in cells expressing the HA-tagged version of GGA1 after staining with the HA antibody.
| |
RESULTS |
|---|
|
|
|---|
Two-Hybrid Screening
To identify proteins that interact with the active
(GTP-bound) conformation of human ARF3, we initiated a two-hybrid
screen in yeast with the use of [Q71L]ARF3, fused to the Gal4 binding domain at the C terminus, as bait. ARF3 was used because it and ARF1
are the most abundant isoforms expressed in most cells and are >97%
identical. This mutant was used because it is resistant to GTP
hydrolysis and is more likely to exist in the GTP-bound form in cells
(Kahn et al., 1995
). Both human kidney and B-cell libraries
were screened, as described in MATERIALS AND METHODS, and 23 independently isolated positive clones were obtained. Eleven of
these positive clones fell into one group and have been described in a
separate publication (Boman et al., 1999
). A single clone was identified as POR1/Arfaptin2 (Van Aelst et al., 1996
;
Kanoh et al., 1997
). Of the remaining positive clones, four
encode the first two members of a new protein family, which are
described in more detail below. Three plasmids from the kidney library
contained identical 2.2-kilobase (kb) inserts encoding 495 amino acids
of a novel protein that is not found in GenBank or Swiss-Prot. A fourth
clone contained a plasmid with a 1.6-kb insert from the B-cell library
that encoded 500 amino acids of another novel protein. The two ORFs had
extensive sequence similarities, as described in more detail below.
Database (GenBank, Swiss-Prot, and dbEST) searching with each of these
sequences revealed significant homology throughout the lengths of each
ORF with a third ORF, which is present as an unknown but fully
sequenced human cDNA in GenBank (accession number KIAA0154). The
KIAA0154 cDNA was obtained, subcloned into pACT2, and found to interact
strongly with [Q71L]ARF3. Because of the high degree of sequence
relatedness between these three sequences, and for reasons explained in
more detail below, we named the proteins Golgi-localizing,
-adaptin
ear homology domain, ARF-binding proteins: GGA1 (kidney clones), GGA2
(B-cell clone), and GGA3 (KIAA0154). The cDNA sequences of each of the
GGAs have been deposited in GenBank. The accession numbers are
AF190862, AF190863, and AF190864 for GGA1, GGA2, and GGA3, respectively.
Based on sequence homology with GGA3 and typical for large cDNAs pulled from two-hybrid libraries, the clones encoding GGA1 or GGA2 were truncated at their 5' ends. Alignment of the N-terminal regions revealed 60-75% identity, but GGA3 had an extension of 100-150 amino acids. The sequence of the 5' end of GGA2 was determined on the computer (and later confirmed by direct DNA sequencing of a full-length clone), whereas 5' rapid amplification of cDNA ends was performed to determine the 5' end of the ORF of GGA1.
GGA3 Message
Northern blot analysis with the use of full-length cDNA for
GGA3 revealed a single message of ~3.9 kb in all eight tissues tested
(Figure 1), with pancreas, brain,
skeletal muscle, and placenta the most abundant sources. The GenBank
sequence KIAA0154 is 3.8 kb, consistent with this being a full-length
cDNA. In pancreas, a second message of 5.2 kb is apparent. The 5' and
3' untranslated regions (UTRs) of the GGA3 clone are 6 and 1600 bp,
respectively. Searches of the dbEST database identified many sequences
identical to KIAA0154 at the 3' end, consistent with the ubiquity of
the message seen in Northern blots, but none that extend the length of
the 5' UTR.
|
GGA2 Message
Northern blot analysis of GGA2 revealed a doublet at 3.4/3.1 kb in all tissues, a less prominent third band at 5.5 kb, and an even weaker signal seen at ~7.5 kb (Figure 1). The 3.4-kb band was the most abundant. A cDNA sequence of 3.3 kb for GGA2 was pieced together by sequential BLAST analyses of the dbEST database. Multiple expressed sequence tags (ESTs) overlapped with the 5' region of our known GGA2 sequence. Clone zs05e07 was the longest among several clones that appeared to start within five bases of one another and contained a putative initiating methionine in frame with our GGA2 sequence. Clone zs05e07 was obtained, sequenced to confirm the ORF, and used for subcloning of full-length GGA2. GGA2 has a very short (23-base) 5' UTR. The dbEST database contains clones from many libraries that are identical to our GGA2 sequence, suggesting that this is the correct sequence of GGA2.1 Altogether, the GGA2 contig spanned 3.3 kb, consistent with the major band on Northern blots.
GGA1 Message
Northern blot analysis indicated a single GGA1 message, 3.0 kb in length, present in all eight tissues (Figure 1). The 2.2-kb inserts from the library plasmids encoding GGA1 contained a 3' UTR of 860 bp. Based on alignment with many EST clones, this appears to be the entire 3' UTR. Hence, we predicted that up to 800 bases at the 5' end of GGA1 were absent from our library plasmid. No sequences in the dbEST database overlapped with the 5' end of GGA1, so 5' rapid amplification of cDNA ends was performed with the use of a human brain cDNA library, as described in MATERIALS AND METHODS. The longest of the sequenced clones (~650 bp) contained a putative start methionine in frame with the GGA1 ORF and 16 bases of 5' UTR. The size of the predicted full-length message [2.8 kb without the poly(A) tail] is consistent with the size of the message determined by Northern blotting. The combination of alignment with the other two GGAs, short 5' UTRs, and the fact that they accounted for nearly all the message seen in Northern blots led us to conclude that we had the full-length ORFs for all three cDNAs.
GGA Proteins
The ORFs of the GGA1, GGA2, and GGA3 cDNAs encode proteins with
predicted molecular masses of 70.4, 67.2, and 74.5 kDa, respectively. Alignment of these predicted proteins (Figure
2A) led us to organize the sequences into
three regions, as shown in Figure 2B. The N-terminal domains of ~300
amino acids are 60-75% identical to one another (pairwise) and
contain stretches of up to 15 residues of absolute conservation. One
gap of 33 amino acids was inserted into the GGA3 sequence for this
alignment (indicated by a dash in Figure 2B). Both the COILS (Lupas
et al., 1991
) and PSORTII (Nakai and Kanehisa, 1992
)
programs predict the presence of a coiled-coil domain in all three GGA
proteins that align in Figure 2A (residues 187-228, 205-243,
and 155-199 in GGA1, GGA2, and GGA3, respectively). Domain searching
revealed the presence in the N termini of all three GGA proteins of
homology with the "HRS domain" or "VHS domain" present in
VPS-27, HRS, and STAM proteins. The middle domains, ranging in size
from 150 to 280 amino acids, are divergent from one another, with
little sequence identity to each other or to other known proteins. The
C-terminal 150 amino acids are 54-68% identical to each other. This
C-terminal domain also has homology to the "ear domain" of
-adaptin, a subunit of the clathrin adaptor complex AP-1, with 44%
amino acid identity and 70% homology over 73 residues at the C termini
(Figure 2A). BLAST searches identified a rat homologue of GGA1 that is
nearly identical in protein sequence and several mouse ESTs and two
potential yeast (Saccharomyces cerevisiae) homologues that
are each >20% identical.
|
To determine which domain(s) was required for binding to ARF3,
full-length GGA1 and a series of deletion constructs of all three GGAs
were subcloned into pACT2 and tested for
-galactosidase activity in
two-hybrid assays with [Q71L]ARF3 (Figure
3). Expression of each of these
constructs was confirmed by immunoblotting of yeast
extracts with the HA antibody. The C-terminal domains were not involved
in the interaction with [Q71L]ARF3, because this domain alone had no
activity in this assay and deletion of this region from any of the GGAs
was not detrimental to interaction (Figure 3). Rather, removal of this
domain increased the strength of the two-hybrid signal between
[Q71L]ARF3 and each of the GGAs. Further truncations from the C
termini to include the middle, divergent domain neither enhanced nor
reduced the interaction with [Q71L]ARF3. In contrast, deletion of the
first half of the N-terminal conserved domains eliminated the
interaction with [Q71L]ARF3 (Figure 3). We conclude that the
N-terminal regions of GGA proteins contain the ARF-binding domains.
Based on the results of truncations of the N-terminal domain of GGA3,
and if we assume that the ARF-binding domain is homologous in all three
GGA proteins, we can further limit the site of interaction to residues
114-274, 130-290, and 80-240 of GGA1, GGA2, and GGA3, respectively.
Homology searches with this portion of each GGA did not identify any
proteins known to bind ARFs or of likely biological significance. Note
that this region overlaps the predicted coiled-coil domain described
above (residues 187-228 of GGA1).
|
GGA1 Binds Directly to ARF3 in a GTP-dependent Manner
To confirm that the interactions between ARF3 and GGA proteins are 1) direct, 2) dependent on GTP binding to ARF, and 3) independent of the [Q71L] mutation, an in vitro GST-affinity binding assay was developed. GST fusions of each GGA protein were expressed in bacteria. All three fusion proteins were expressed at high levels in bacteria. However, GST fusions of GGA2 and GGA3 were insoluble, whereas GST-GGA1(145-639) was soluble in bacterial lysates. The reasons for this difference in solubility are unknown. Efforts then focused on the GGA1 fusion protein for biochemical analyses.
We first tested whether ARF3 could be retained in a GTP-specific manner
by GST-GGA1(145-639) on glutathione-agarose beads. Purified ARF3
(wild-type or the [Q71L] mutant) was preloaded with either GTP
S or
GDP and then incubated with GST-GGA1 on glutathione-agarose beads.
ARF3·GTP
S was retained by GST-GGA1(145-639) (Figure
4) but not by GST alone. In contrast,
ARF3·GDP was not retained by either GST-GGA1(145-639) (Figure 4) or
GST. Identical results were obtained for both wild-type and
[Q71L]ARF3. These results reveal that ARF3 binds directly to GGA1 in
a GTP-dependent manner and that the interaction does not require
mutation of glutamine 71. We also assayed GST-GGA1(145-639) for ARF
exchange factor and ARF GAP activity and found it devoid of each.
|
Localization of GGA1
Antibodies to GGA1 were raised in rabbits with the use of purified
GST-GGA1(145-639) as the antigen. These antisera were characterized with respect to specificity and sensitivity by
immunoblotting. A 1:2000 dilution of serum (R-79709)
was able to detect 1 ng of GST-GGA1(145-639) as a major band at the
expected, apparent molecular mass of 90 kDa (Figure
5A, left lane). Western blots of NRK
lysates identified two prominent bands of 72 and 78 kDa (Figure 5A,
center lane) that were blocked by preincubation of the antibody with antigen. Overexpression of full-length GGA1 in NRK cells caused a clear
increase in immunoreactivity of the 78-kDa band, with no change in the
lower immunoreactive band (Figure 5A, right lane). Note that the
development times for the immunoblots of NRK lysates in
Figure 5A (center and right lanes) were quite different; otherwise, the
signal from the overexpressed GGA1 would completely obscure the
cross-reactive 72-kDa band. In other experiments, GGA2 and GGA3 were
also overexpressed in NRK cells, and no change in immunoreactivity was
detected with R-79709. We conclude that the band migrating as a 78-kDa
species is full-length GGA1 and that the GGA1 antibodies do not
strongly cross-react with the other members of this family.
|
NRK cells were fractionated by differential centrifugation to yield crude nuclear, mitochondrial, other membranous, and cytosol protein fractions (Figure 5B). Note that the nuclear fraction is simply a low-speed spin that also contains unbroken cells. The 78-kDa band, corresponding to GGA1, is predominantly soluble because it partitions into the S100 fraction, with some also present in the nuclear fraction. In contrast, the 72-kDa band was found only in the nuclear and mitochondrial fractions. The clear differences in fractionation are consistent with the 72-kDa band being a cross-reacting protein.
The localization of both endogenous and overexpressed GGA1 was
studied in cultured mammalian cells (Figure
6). Weak perinuclear staining of
endogenous GGA1 was observed when NRK, CHO, or HeLa cells were stained
by indirect immunofluorescence (Figure 6A). Perinuclear staining of
endogenous or overexpressed GGA1 was lost by preincubating the
antiserum with recombinant GST-GGA1(145-639) (Figure 6B). The
perinuclear staining was increased markedly, but otherwise was very
similar to endogenous staining, after cells were either microinjected
(Figure 6D) or transfected (see Figures 8-10) with vectors
directing expression of full-length GGA1. When the overexpressed
protein was GGA1 carrying the HA epitope at the N terminus, we obtained
images with the GGA1 antibody and the HA antibody that were
indistinguishable (Figure 7, compare A
and G with D). Together with the evidence that GGA1 is predominantly a
soluble protein, these data support the conclusion that GGA1 is
peripherally associated with membranes that reside in the perinuclear region.
|
|
A number of other antibodies were then used for indirect immunofluorescence to further define the location of GGA1 in cultured cells. NRK cells overexpressing either wild-type or HA-tagged GGA1 were used because their specific signals were much stronger. Double staining with GGA1 and mannosidase II antibodies revealed very similar patterns. However, when the images were overlaid, it became clear that these two antisera stained overlapping but distinct compartments (Figure 7, D-F). Because mannosidase II is a lumenal marker for the medial-Golgi stacks and the GGA1 staining was so similar, it was likely that GGA1 was simply localizing to distinct stacks in the Golgi.
When cells were costained with GGA1 and TGN38 antisera, we saw patterns that were superimposable when the images were overlaid (Figure 7, A-C). Antibodies directed against two other markers of the TGN, M6PR and AP-1, were also found to colocalize with GGA1. Thus, we conclude that GGA1 is localized primarily to the TGN.
The localization of GGA1 to the TGN was extended to include TGN-derived
vesicles by costaining of NRK cells with GGA1 and AP-1 antibodies. Both
antibodies stained the TGN. In addition, the punctate, vesicular
staining in the cytosol, described above for the GGA1 antibody,
overlaid extensively with the AP-1 staining. In contrast, antibodies
directed against the
-adaptin subunit of AP-2 did not colocalize
with GGA1.
We also tested for GGA1 colocalization with ARFs. ARFs were originally
shown to localize to the cis- and medial-Golgi (Stearns et al., 1990b
), and more recent evidence supports the
presence of ARFs on the TGN (Stamnes and Rothman, 1993
; Traub et
al., 1993
; Hirst and Robinson, 1998
). When cells were stained with
the monoclonal anti-ARF (1D9) antibody and the GGA1 antiserum,
there was clear overlap in the high-density staining of each around the
nucleus, consistent with partial colocalization of GGA1 and ARFs
(Figure 7, G-I). However, the punctate staining throughout the
cytosol, detected with 1D9 and seen with overexposure of anti-GGA1
images, did not colocalize.
The sensitivity of Golgi-localized proteins to the fungal metabolite
BFA has been correlated with in vivo ARF interaction, because BFA can
inhibit some ARF exchange factor activities (Peyroche et
al., 1996
, 1999
; Togawa et al., 1999
). NRK cells
overexpressing GGA1 were treated with BFA and then fixed and stained
with GGA1 and mannosidase II,
-COP, or ARF antibodies. The
mannosidase II distribution is sensitive to this concentration of BFA
only after >5 min.
-COP and ARF staining have been shown previously to be peripherally associated with Golgi membranes and rapidly (0.5-5
min) dissociate upon exposure of NRK cells to BFA (Donaldson et
al., 1992
; Zhang et al., 1994
). Within 1 min of BFA
treatment, endogenous and overexpressed GGA1 (Figure 6C), ARF, and
-COP staining in the perinuclear region all become more diffuse.
Within 5 min, nearly all of the GGA1 and
-COP staining was diffuse, whereas the mannosidase II staining of the Golgi stacks was intact. These data are consistent with a model in which the localization of
GGA1 to the Golgi compartment is ARF dependent.
Localization of GGA2 and GGA3
Because we still lack antisera specific for GGA2 or GGA3, we
determined the location of transiently expressed, N-terminal, HA
epitope-tagged versions of the two proteins. In each case, the densest
staining was seen near the nucleus, similar to staining seen with the
GGA1 antiserum (Figure 8). This
perinuclear staining was also revealed to be BFA sensitive in each
case, because it was quickly (<5 min) dispersed by exposure to 10 µM
BFA (Figure 8, E and F).
|
Furthermore, the GGA2 and GGA3 staining were coincident with the
staining of TGN38 (Figure 8), M6PR, and AP-1 and overlapped with
mannosidase II and
-COP staining. Similar results were obtained in
NRK, CHO, and HeLa cells. That all three GGAs localize to the same
membranes was confirmed when NRK cells were transfected with plasmids
directing expression of both GGA1 and GGA2-HA or GGA1 and GGA3-HA and
indirect immunofluorescence was performed with both GGA1 and HA
antibodies (Figure 9).
|
Although the densest staining for all three GGAs was in the TGN, there were also distinct features of the staining of each GGA. GGA1 exhibited very little punctate staining in the cytosol. GGA3 displayed distinct punctate staining in cytosol that did not colocalize with markers of mitochondria, ER, or cis-Golgi. In contrast, GGA2 was predominantly seen as punctate spots that were more diffusely arranged, i.e., less concentrated around the nucleus. Diffuse staining throughout the cell was also evident, although it is difficult to see in the figures. In all three cases, the BFA sensitivity was observed only for the perinuclear TGN staining and not for the punctate staining in the cytosol.
Relationship between ARF Activity and GGAs at the Golgi
The induced expression of the dominant activating mutant of ARF1
(Zhang et al., 1994
), ARF3, or ARF4 (C. Zhang and R.A. Kahn, unpublished observations) in mammalian cells causes dramatic expansion of the ER, causes engorgement and vesiculation of the Golgi stacks, inhibits protein secretion, and blocks protein exit from the ER (Dascher and Balch, 1994
; Zhang et al., 1994
). These effects
have been proposed to result from the ARF-induced recruitment of the COP-I coats, which lack the ability to uncoat, as a result of the lack
of GTP hydrolysis by these mutated ARFs. We reasoned that the increased
presence of GGAs at the same membranes should either exacerbate (if
GGAs and COP-I both function in a common pathway) or oppose (if GGAs
and COP-I function in distinct pathways) these effects of the
activating mutant on vesicular traffic and organelle morphology.
NRK cell lines that had been stably transfected with a plasmid that
allowed the interferon-inducible expression of [Q71L]ARF1 were used
(Zhang et al., 1994
). Increased expression of GGA1 in these
cells was achieved by either microinjection of GST-GGA1(145-639) or
transient transfection of the pcDNA3.1-based vector, with similar results, and was visualized with either FITC-dextran or staining with
R-79709. In untransfected or mock-transfected cells,
[Q71L]ARF1-expressing cells have dramatically swollen and expanded
Golgi, when visualized with ARF antibodies, as described previously
(Zhang et al., 1994
) and shown in Figure
10. In contrast, the Golgi in cells
that overexpress GGA1 do not expand or vesiculate and look very much
like control NRK cells when viewed by light microscopy (Figure 10).
Thus, instead of enhancing the effects on Golgi morphology that are
associated with the expression of [Q71L]ARF1, GGA1 overexpression
prevented these changes in Golgi structure. These data support the
conclusions that GGA1 is active at Golgi membranes and can act
antagonistically to the ARF effector(s) that promotes Golgi
expansion/vesiculation.
|
Role of GGA1 in Membrane Traffic
Both M6PR and TGN38 are transmembrane proteins that cycle
between the TGN and the cell surface, with the majority of staining normally evident at the TGN of NRK cells. The overexpression of GGA1
caused a reduction of TGN38 staining at the TGN that approached a
complete loss of staining in some cells (Figure
11, A and B). This effect was similarly
observed with the overexpression of GGA3 (Figure 11, E and F). Although
decreased staining in the perinuclear region was clear and observed
consistently, increased TGN38 staining at the plasma membrane was not
always evident. We conclude that this is the result of more diffuse
distribution over the entire cell surface. When cells were stained for
M6PR, a variety of effects were apparent, correlating with the amount
of GGA1 expressed in each cell. The predominant effect was a
redistribution of M6PR from the TGN to a primarily plasma membrane
location in GGA1-overexpressing cells (Figure 11, C and D). This
experiment was also performed with HA-GGA3, and an even more dramatic
redistribution of M6PR receptors was observed (Figure 11, G and H); in
this instance, the increased staining at the plasma membrane is
evident.
|
Both
-COP, a marker for COP-I, and p58, a marker for the
intermediate compartment, cycle between the intermediate compartment and the cis-Golgi and were monitored for changes in
localization upon GGA1 overexpression. The distribution and intensity
of p58 staining were unaffected by GGA1 overexpression, whereas the
distribution and intensity of
-COP were only moderately affected by
excess GGA1. Specifically, the
-COP signal at the Golgi was reduced slightly, but the punctate, more diffuse cytosolic staining was unaffected. At the highest levels of GGA1 expression, the morphology of
the Golgi, as seen with mannosidase II staining, was altered, i.e., it
became smaller, more diffuse, and, in a few instances, lost all
discernible Golgi stacks.
| |
DISCUSSION |
|---|
|
|
|---|
We describe the isolation and initial characterization of three
members of a new family of ubiquitously expressed ARF effectors in
mammalian cells, termed GGAs. The conclusion that these are direct
effectors of ARF signaling in cells is based on several criteria: 1)
GGAs bind directly to ARFs in a GTP-dependent manner in both the yeast
two-hybrid assay and on an affinity matrix; 2) localization in intact
cells and sensitivity to BFA are consistent with interaction with ARFs;
3) increased expression leads to changes in membrane traffic,
particularly in the region of the TGN; and 4) they share a region with
sequence homology to
-adaptin, a component of the AP-1 tetrameric
coat complex and a putative effector for ARF action in cells. We
propose that GGAs are involved in the regulation by ARFs of vesicular
traffic exiting the TGN and discuss potential overlap between GGAs and
other putative ARF effectors.
The full-length ORFs of all three GGA proteins were cloned from human tissue sources and encode proteins that are similar in length, roughly 33% identical when all three are aligned and 37-47% identical in pairwise alignments. They also have N- and C-terminal regions of 300 and 150 residues, respectively, that are 55-75% identical. ARFs bind to the conserved N-terminal domain. Both Northern blot data from a variety of human tissues and the presence of multiple EST sequences from libraries, derived from a variety of tissues, are consistent with all three GGAs being expressed in a wide variety of human tissues. Other than the similarities in sequence among the GGAs, there was little functional information gleaned from the sequences themselves.
One interesting exception to this are the C termini of GGAs, which
possess significant (44% identity and 70% homology over 73 residues)
homology with the ear domain of
-adaptin, a subunit of the AP-1
complex. This region of
-adaptin is divergent from the other large
subunits of the AP complexes. Some TGN-targeting information resides in
the ear domain, although it appears to be secondary to targeting
signals in the N-terminal domains of
- and
-adaptins (Page and
Robinson, 1995
). An intriguing possibility for the GGAs is that the
C-terminal domain is involved in interactions with other (unknown)
proteins to specify their localization at the TGN. We are currently
testing this hypothesis. Other possible functions of the
-adaptin
ear involve proper assembly with the other adaptin subunits, although
not through direct protein-protein interactions, and the assembly of
adaptin multimers (Page and Robinson, 1995
). Preliminary efforts to
identify protein complexes containing GGA1, including
immunoprecipitation and gel filtration chromatography, have not proven
productive. Should conditions be found to stabilize such a (potential)
protein complex, it will be possible to determine the presence of ARFs
under different conditions. Alternatively, it is possible that the
biologically important interactions of GGAs require membrane
association, making their identification by copurification more
problematic. The colocalization of GGA1 and AP-1 in vesicles argues
against the GGAs serving as adaptors for a distinct group of vesicles
leaving the TGN and provides a useful source for further dissection of
GGA-containing protein complexes.
The binding of ARF to the GGA proteins was found to be highly specific
and almost certainly regulated in cells. In addition to the controls
built into the two-hybrid screen, we also found that all ARF isoforms
interact well with GGAs but that the structurally related ARF-like
(Arl) proteins (Arl1 and Arl2; 40-50% identical to ARFs) do not
(Boman et al., 1999
). The facts that all three GGAs
preferentially interacted with the activated mutant of ARF3 over the
wild-type protein and that GST-GGA1(145-639) bound ARF3 in a
GTP-dependent manner on an affinity matrix are consistent with the
proposed role of GGAs as immediate downstream effectors of ARF proteins.
Three lines of experimental evidence support the conclusion that ARFs
and GGAs colocalize in cells. First, double labeling of fixed cells
with antibodies to ARFs and GGAs revealed evidence of overlap in their
locations in cells. Compared with other markers of organelles, it is
clear that the highest concentration of GGA1 is at the TGN, and ARFs
have been physically and functionally localized to this compartment
(Stearns et al., 1990a
). Epitope tagging of GGA1 was shown
to have no detectable effect on the localization of this protein; by
extension, we tentatively conclude that the same will hold true for
GGA2 and GGA3. When the N-terminal-tagged GGA proteins were
transiently expressed in mammalian cells, they colocalized in large
part with TGN markers, but each protein also revealed additional
staining: faint punctate cytosolic staining with HA-GGA1, which is more
pronounced with HA-GGA3, and more scattered punctate staining around
the TGN and more diffuse staining throughout the cell with HA-GGA2.
Thus, although all three GGAs are present on TGN membranes and
partially colocalize with ARFs, each may also migrate to a distinct
location likely to be functionally related to the TGN.
Second, the localization of GGAs to the TGN is rapidly and reversibly
blocked upon exposure to BFA. Because the only clearly identified
targets for BFA are ARF exchange factors (Peyroche et al.,
1999
), which are inhibited upon binding of BFA, it is currently thought
that the actions of BFA on cells follow from a deficiency of active
ARF. Thus, we conclude that the localization of GGAs at the TGN is
dependent on their binding to activated ARF. Although the most
intensively studied aspect of BFA action is the ARF-dependent
recruitment of COP-I to Golgi membranes, it is also known that BFA
induces alterations in the localization of markers of the TGN,
specifically M6PR, resulting in increased staining at the plasma
membrane. The recruitment of other coat complexes, specifically AP-1
(Stamnes and Rothman, 1993
; Traub et al., 1993
), AP-3
(Simpson et al., 1997
; Faundez et al., 1998
; Ooi
et al., 1998
), and AP-4 (Dell'Angelica et al.,
1999
; Hirst et al., 1999
), has also been shown to be BFA
sensitive and, thus, predicted to require active ARF.
Third, and somewhat paradoxically, we found that when GGA1 was
transiently overexpressed in NRK cells, there was a clear enhancement in the staining of ARF at the TGN (Zhu et al., 2000
). The
simplest interpretation of this observation is that the effectors
(GGAs) bind and stabilize the active conformation of ARFs, leading to the accumulation of the activated form of ARF, but an alternative explanation has also been proposed (Zhu et al., 2000
). Thus,
we conclude that the GGAs have all the characteristics of immediate downstream effectors that mediate the actions of ARF at TGN membranes.
The identification of the three GGA proteins binding to the TGN brings
to at least seven the number of different proteins, or protein
complexes, that are regulated by interactions with ARFs at the Golgi:
COP-I, AP-1, AP-4, PLD1, and the three GGAs. This high density of ARF
effectors begs the question of how specificity in signal propagation is
achieved in intact cells. To begin to address this question, we first
asked if GGAs were mediators of one or more of the activities of ARF at
the Golgi, all of which were ascribed previously to recruitment of coat
proteins, e.g., COP-I or AP-1, or activation of phospholipase D (PLD1).
The inducible expression of the dominant activated ARF mutant
[Q71L]ARF1 in mammalian cells has been shown to cause enlargement of
the ER and the Golgi lumen, vesiculation of the Golgi into
heterogeneously sized vesicles and later cell death (Zhang et
al., 1994
), and inhibition of protein export from the ER (Dascher
and Balch, 1994
). If GGAs are mediators of one or more of these
phenotypes, we predicted an exacerbation of these morphological changes
upon overexpression. In contrast, overexpression of any of the GGAs
prevented this dramatic Golgi expansion induced by [Q71L]ARF1
expression (Figure 10). This effect is further evidence of a functional
interaction between GGAs and ARFs in cells, but rather than being
mediators of the Golgi expansion, GGAs mediate a distinct pathway that
can compete with the mediator(s) of Golgi vesiculation, perhaps by direct competition for the binding of the activated ARF. Thus, in
contrast to COP-I and PLD1, which may each work in a single ARF-regulated pathway, the GGAs are likely to mediate a distinct process from these two other ARF effectors. In a related study (Kuai
et al., 2000
), a series of mutations in the switch I and II
regions of ARF3 were characterized with regard to differential effector
interactions. These mutants allowed the functional separation of
defects in binding to GGAs, recruitment of COP-I, and activation of
PLD1, supporting the conclusion that none of these five effectors (PLD1, COP-I, or the three GGAs) can be the sole mediator of the Golgi
vesiculation caused by an excess of ARF activity.
By monitoring the effects of GGA overexpression on a variety of markers
of the secretory pathway, we conclude that the primary site and role of
GGA action is most likely the regulation of protein export from the
TGN. The redistribution of both TGN38 and M6PR, both transmembrane
proteins, away from the TGN is among the strongest evidence to support
this model. This effect is most evident in cells that overexpress GGA3.
This conclusion is further supported by the observation that GGA1
colocalizes with AP-1 but not with AP-2. With high levels of GGA
expression, we also observed changes in the markers of the
cis- and medial-Golgi:
-COP and mannosidase II,
respectively. We take this as further evidence that the functions of
GGAs in cells include the regulation of vesicular transport. We have
not detected any changes in the staining of PDI (a marker for the ER
lumen) or p58 (a marker for the intermediate compartment) with
overexpression of any GGA protein.
In several, but not all, experiments, the increased expression of any of the three GGA proteins caused a decrease in the staining of transferrin or transferrin receptors (A.L. Boman, C.-j. Zhang, and R.A. Kahn, unpublished observation). This may suggest the ability of GGA proteins to modify the recycling endosome pathway, but it is apparently at odds with the observation that GGA1 does not colocalize with AP-2. Although we conclude that the compartments that are affected first and most dramatically by increased GGA expression are those in the TGN-endosome secretory pathway, we clearly cannot exclude actions of GGAs at other membrane sites. Indeed, the findings that GGA1 is soluble and likely recruited to membranes along with ARFs and that ARFs are active at virtually all membranes in cells make it likely that GGAs will be found to have roles in vesicular transport at other sites as well.
Another aspect of the complexity of ARF signaling at Golgi/TGN
membranes is that we anticipate either that some level of ARF isoform
specificity must exist or, more likely, that recruitment involves
additional factors that may be differentially localized or regulated.
Candidates for the latter possibility include ARF GAPs, because
evidence has recently been presented (Goldberg, 1999
) that supports the
simultaneous binding of ARF GAP and COP-I to activated ARF. The
apparent redundancy in the GGA family offers another possible
explanation for or source of its specificity, and the differences in
staining between the different GGAs offer preliminary evidence for
specific differences in their actions.
Clearly, one of the challenges in the near future is to determine the
relationship between the ARF-dependent recruitment of GGAs and coat
complexes to Golgi membranes. Our choice of M6PR as marker for the TGN
was not arbitrary, because M6PRs have been implicated as regulators of
AP-1 recruitment. With the discovery of a role for ARF in AP-1
recruitment, it was proposed that ARFs activate M6PRs to promote coat
formation at the TGN (Le Borgne et al., 1993
; Le Borgne and
Hoflack, 1997
). The use of M6PR-deficient cell lines to assess the
requirement for M6PR in AP-1 recruitment has led to conflicting
conclusions (Le Borgne and Hoflack, 1997
; Zhu et al., 1999
).
One model proposes that activated ARF initiates the formation of a
specific binding site for AP-1, which in turn binds clathrin to promote
the maturation of the budding vesicle. With the discovery of three new,
direct binders of ARF·GTP at the TGN (the GGAs), we speculate that
the recruitment of GGAs to the TGN may be a prerequisite for adaptin
complex binding or that the binding of GGAs and adaptins could occur
simultaneously. We are currently testing this and related models in an
effort to provide more direct evidence for the roles of ARFs and GGAs in membrane traffic at the TGN.
| |
ACKNOWLEDGMENTS |
|---|
We thank the following people for their gifts of reagents: S. Elledge (two-hybrid plasmids and yeast strains), R. Brazas (plasmid pBG4D), K. Moremen and M. Farquhar (mannosidase II antisera), L. Traub (AP.6 antibody), K. von Figura (M6PR antibodies), G. Banting (p58 antibody), and L. Zhang and H. Fu (plasmid). We also thank the other members of the Kahn laboratory for helpful discussions and R. Ahmed for the use of his microscope during the early phases of this work. It was discovered during the preparation of this article that Margaret Robinson and colleagues have similar data on the characterization of GGA proteins, and we acknowledge and appreciate the collegial sharing of information that resulted.
| |
FOOTNOTES |
|---|
* Present address: Department of Biochemistry and Molecular Biology, University of Minnesota, Duluth, MN 55812.
Corresponding author. E-mail address:
rkahn{at}bimcore.emory.edu.
1 During the preparation of this article, it was noted that a new, apparently full-length protein sequence corresponding to GGA2 had appeared in GenBank (accession number AAC05813) as a result of sequencing of genomic human DNA from chromosome 16p12. The encoded protein is the same length as GGA2 and is nearly identical to our GGA2 sequence. Only two differences were noted: our residue tryptophan 281 is a proline and our proline 425 is an alanine in AAC05813. The sources of these differences are unknown, but these data otherwise agree with the sequence we obtained.
| |
ABBREVIATIONS |
|---|
Abbreviations used:
ARF, ADP-ribosylation factor;
BFA, brefeldin
A;
bp, base pairs;
EST, expressed sequence tag;
GAP, GTPase-activating protein;
GGA, Golgi-localizing,
-adaptin ear
homology domain, ARF-binding protein;
GST-GGA1(145-639), fusion
protein consisting of GST and amino acid residues 145-639 of GGA1;
kb, kilobase;
M6PR, mannose 6-phosphate receptor;
NRK, normal rat kidney;
TGN, trans-Golgi network;
UTR, untranslated region.
| |
REFERENCES |
|---|
|
|
|---|